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Letters to the Editor
A Promising Target for Treatment of Multidrug-Resistant Bacterial Infections
Multidrug-resistant infections pose a major quandary for
clinicians by complicating therapy choice, compromising pa-
tient recovery, and creating a serious threat to public health
(1). In Gram-negative bacteria, resistance to almost all -lac-
tam antibiotics, including the carbapenems, can be conferred
by metallo--lactamases (MBLs), such as imipenemase (IMP),
Verona imipenemase (VIM), German imipenemase (GIM),
New Delhi MBL (NDM), and Sa˜o Paulo MBL (SPM), which
are invariably accompanied by additional resistance mecha-
nisms. The ease with which multidrug resistance disseminates
among Gram-negative pathogens is illustrated by the rapid
global spread of NDM-1 (5). For patients infected with MBL-
positive (MBL) bacteria, last-resort compounds such as tige-
cycline and colistin offer the only means of treatment, and, in
the case of colistin, often at the cost of serious side effects.
Moreover, tigecycline is currently not licensed for treatment of
urinary tract infections, the primary infection associated with
NDM-1 bacteria, and neither agent is 100% effective for all
MBL strains. There is thus an urgent need for novel and safe
antibiotics that are effective in controlling these “super-bug”
infections.
One potential target for new-generation antibiotics are the
seven enzymes of the 2-C-methyl-D-erythritol 4-phosphate (MEP)
or nonmevalonate pathway of isoprenoid biosynthesis, an es-
sential metabolic route in many Gram-negative and Gram-
positive bacteria and in malaria parasites (3, 4). The compound
3-(N-formyl-N-hydroxyamino)propyl-phosphonic acid (fosmido-
mycin), a specific inhibitor of the first step in the MEP path-
way, was described in the 1980s as an effective antibacterial
agent and has more recently been the subject of clinical trials
demonstrating its safety and potency in malaria patients (6). Of
note, fosmidomycin not only has a direct antimicrobial effect
but may also possess immediate anti-inflammatory properties
by inhibiting  T-cell-driven immune responses to the MEP
pathway intermediate, (E)-4-hydroxy-3-methyl-but-2-enyl
pyrophosphate (HMB-PP) (2).
Here we report the first evidence of activity of fosmidomycin
against multidrug-resistant bacteria with acquired MBL genes.
Our data demonstrate that irrespective of MBL type and ori-
gin, all isolates of Enterobacter cloacae, Escherichia coli, Kleb-
siella pneumoniae, and Pseudomonas aeruginosa tested were
susceptible to fosmidomycin, including laboratory-generated
colistin-resistant derivatives (Table 1). Control strains not pos-
sessing the MEP pathway, such as Chryseobacterium indolo-
genes, were not affected by fosmidomycin. As the MICs defined
here are achievable in vivo (7), our findings suggest that fos-
midomycin and related compounds might be useful in the
clinic and help reduce the exposure of patients to the toxic side
effects of colistin and the risk of generating colistin-resistant
mutants. Taken together, we provide proof of concept that
fosmidomycin and other MEP pathway inhibitors represent
promising leads for future drugs by targeting an essential met-
abolic route that is shared by the majority of pathogenic bac-
teria, including multidrug-resistant clinical isolates, but is ab-
sent in humans.
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TABLE 1. Susceptibility of multidrug-resistant bacteria to fosmidomycina
Species Gramstain MEP Isolate Origin MBL
MIC (g/ml) for:
Azt Amk Gen Mer Imp Fof Fos
Enterobacter cloacae   481234 Brazil IMP-1 0.19 2 12 3 3 32 1
69–7329 Brazil IMP-4 6 1.5 1.5 12 3 32 1
IR19 India NDM-1 64 64 32 32 32 16 32
IR36 India NDM-1 64 64 32 32 32 32 8
IR38 India NDM-1 64 64 32 32 32 32 2
IR44 India NDM-1 64 64 32 16 16 32 4
IR59 India NDM-1 64 64 32 32 32 32 4
Escherichia coli   IR9 India NDM-1 64 64 32 32 16 0.38 32
IR31 India NDM-1 64 64 32 32 16 ND 64
IR60 India NDM-1 64 64 32 16 16 32 16
IR62 India NDM-1 64 64 32 32 32 16 64
Klebsiella pneumoniae   WCH7 Greece IMP-4 0.064 2 2 1 0.75 32 32
IR17 India NDM-1 64 6 32 32 32 24 32
IR17-D* India NDM-1 ND ND ND ND ND ND 32
K1 India NDM-1 64 64 32 32 32 6 8
K1-D* India NDM-1 64 64 32 24 16 8 32
K7 India NDM-1 64 64 32 32 32 32 16
Pseudomonas aeruginosa   A1 Brazil SPM-1 6 64 32 32 32 32 8
A22 Brazil SPM-1 12 64 32 32 32 32 16
A25 Germany GIM-1 12 4 12 32 32 12 16
A31 Greece VIM-1 48 64 32 32 32 12 8
A37 Italy VIM-1 8 64 32 32 32 16 4
A41 Italy VIM-1 8 64 32 32 32 32 8
A57 Italy VIM-1 8 64 32 32 16 12 8
A63 France VIM-2 4 64 32 32 32 32 32
A67 Poland VIM-2 6 32 32 32 32 2 4
A70 Russia VIM-2 8 64 32 32 32 16 8
Chryseobacterium indologenes   S281 UK ND ND ND ND ND ND 128
Enterococcus faecalis   IQA UK ND ND ND ND ND ND 128
Staphylococcus aureus   S288 UK ND ND ND ND ND ND 128
a The majority of clinical isolates were resistant (R) to aztreonam (Azt; R  8 g/ml; R  16 for P. aeruginosa), amikacin (Amk; R  16), gentamicin (Gen; R 
4), meropenem (Mer; R  8), and imipenem (Imp; R  8), as defined by EUCAST. MICs below breakpoints are bold. Fosfomycin (Fof; R  32), a specific inhibitor
of peptidoglycan biosynthesis, was included in the present study as it shares some pharmacokinetic properties with fosmidomycin (Fos) and targets a similar but not
identical spectrum of Gram-positive and Gram-negative species. Fos MICs were determined using the ISO microbroth dilution method accepted by both EUCAST and
CLSI. *, laboratory-generated colistin resistant mutants; ND, not done.
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